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Abstract
Introduction: Secreted Protein, Acidic and Rich in Cysteine (SPARC) is a matricellular protein involved in many biological
processes and found over-expressed in cirrhotic livers. By mean of a genetic approach we herein provide evidence from
different in vivo liver disease models suggesting a profibrogenic role for SPARC.
Methods: Two in vivo models of liver fibrosis, based on TAA administration and bile duct ligation, were developed on
SPARC wild-type (SPARC+/+) and knock-out (SPARC2/2) mice. Hepatic SPARC expression was analyzed by qPCR. Fibrosis was
assessed by Sirius Red staining, and the maturation state of collagen fibers was analyzed using polarized light.
Necroinflammatory activity was evaluated by applying the Knodell score and liver inflammatory infiltration was
characterized by immunohistochemistry. Hepatic stellate cell activation was assessed by a-SMA immunohistochemistry. In
addition, pro-fibrogenic genes and inflammatory cytokines were measured by qPCR and/or ELISA. Liver gene expression
profile was analyzed in SPARC2/2 and SPARC+/+ mice using Affymetrix Mouse Gene ST 1.0 array.
Results: SPARC expression was found induced in fibrotic livers of mouse and human. SPARC2/2mice showed a reduction in
the degree of inflammation, mainly CD4+ cells, and fibrosis. Consistently, collagen deposits and mRNA expression levels
were decreased in SPARC2/2 mice when compared to SPARC+/+ mice; in addition, MMP-2 expression was increased in
SPARC2/2 mice. A reduction in the number of activated myofibroblasts was observed. Moreover, TGF-b1 expression levels
were down-regulated in the liver as well as in the serum of TAA-treated knock-out animals. Ingenuity Pathway Analysis (IPA)
analysis suggested several gene networks which might involve protective mechanisms of SPARC deficiency against liver
fibrogenesis and a better established machinery to repair DNA and detoxify from external chemical stimuli.
Conclusions: Overall our data suggest that SPARC plays a significant role in liver fibrogenesis. Interventions to inhibit SPARC
expression are suggested as promising approaches for liver fibrosis treatment.
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Introduction
Secreted protein, acidic and rich in cysteine (SPARC), also
called osteonectin or BM-40, is a secreted multifunctional
extracellular matrix (ECM)-associated protein involved in a
number of biological processes [1,2]. Among other functions,
SPARC plays a major role in the wound healing response to injury
and tissue remodeling [1]. Regarding mechanisms likely therein
involved, locally produced SPARC was found to stimulate
collagen deposition, inflammatory cells recruitment, TGF-b1
production, mesenchymal cell proliferation and ECM proteins
synthesis, in the context of kidney, skin and/or lung fibrogenesis
[3,4], while no studies were performed on liver fibrosis models.
Due to its biological properties, SPARC was proposed as a
therapeutic target to prevent fibrosis in chronic inflammatory and
profibrogenic conditions [5].
Although SPARC is constitutively expressed in the liver under
non-pathological conditions [6], it was found upregulated in
fibrotic-related liver diseases such as cirrhosis [7,8] and hepato-
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cellular carcinoma [9,10,11]. During liver fibrogenesis, SPARC
was found overexpressed in activated hepatic stellate (HSCs) and
in endothelial cells [6,7]. These findings suggest that SPARC may
have a prominent role in liver fibrogenesis; moreover, we have
recently demonstrated that a forced transitory reduction in
SPARC expression levels by an adenovirus encoding an antisense
specific for SPARC mRNA (AdasSPARC) attenuates fibrosis
development in an in vivo experimental rat model [5].
During liver fibrogenesis TGF-b1 expression is induced. This
cytokine plays a key role in the activation of HSCs and in the
development of hepatic fibrosis [12]. Thus, different molecular
strategies have been explored to block/reduce TGF-b1 mediated
mechanisms including gene transfer of truncated TGF-b1 receptor
type II or administration of a soluble TGF-b1 type II receptor,
[13,14]. Interestingly, a positive feedback between SPARC and
TGF-b1 has been previously reported [3,15].
To further elucidate the role of SPARC in hepatic fibrogenesis,
we have herein used different in vivo disease models, i.e. involving
either hepatotoxicity or biliary duct obstruction, in SPARC
genetically deficient mice. Liver fibrosis development was found
markedly attenuated in SPARC2/2 when compared to SPARC+/
+ mice. Our data suggest that SPARC plays a major role in the
pathogenesis of liver fibrosis, through myofibroblast recruitment/
activation and induction of TGF-b1 expression. Additionally,
microarray analyses likely involve DNA protective and repair
mechanisms. Overall these results give further support to new
therapeutic approaches based on SPARC expression inhibition for
the treatment of patients with chronic liver diseases.
Materials and Methods
Animals and Experimental Design
Male C57BL/6x129SvJ (The Jackson Laboratory, Bar Harbor,
Maine, USA) SPARC+/+ and SPARC2/2 mice (2–3 months-old)
were used. In a hepatotoxic model, animals were administered
intraperitoneally (i.p.) with 200 mg/kg of thioacetamide (TAA)
(Sigma, St Louis, MO), 3 times a week as described previously
[16,17]. Animals were sacrificed at 2 and 10 weeks after TAA
application onset and blood and liver samples were obtained. In a
cholestasis model, mice were subjected to bile duct ligation (BDL)
or sham-operation or they were left untreated. For surgeries,
animals were anesthetized with sodium pentobarbital. A midline
laparotomy was performed and the common bile duct was doubly
ligated with 4–0 silk. Sham operation procedure was similar but
without ligating the bile duct. Animals were sacrificed at 7 days
after surgery and blood and liver samples were obtained. All
experimental procedures were performed according to the ‘‘Guide
for the Care and Use of Laboratory Animals’’ published by the
U.S. National Research Council (National Academy Press,
Washington, D.C. 1996) and approved by the School of Medicine,
Austral University (Permission number: FBA002).
Human Liver Specimens
A total of 7 liver biopsies, from 2 non-cirrhotic and 5
cirrhotic subjects were used in real-time polymerase chain
reaction studies. Cirrhosis etiology was diverse (primary biliary
cirrhosis, biliary atresia, hepatitis C virus (HCV) infection,
hemochromatosis and cryptogenic; patients #1 to #5). All
participants gave their written informed consent to the study,
which was approved by the Institutional Ethics Committee and
by the Ministry of Health of Buenos Aires State (Permission
number: 2919/179/2011).
Reverse Transcription-polymerase Chain Reaction (RT-
PCR)
Liver tissue was homogenized and total RNA was extracted by
using Trizol Reagent (Sigma-Aldrich Co., St. Louis, MO). Total
RNA (2 mg) was reverse transcribed with 200 U of SuperScript II
Reverse Transcriptase (Invitrogen, Carlsbad, CA) using 500 ng of
Oligo (dT) primers. cDNAs were subjected to real-time polymer-
ase chain reaction (qPCR) (Stratagene Mx3005p, Stratagene, La
Jolla, CA, USA). For qPCR of mouse samples the mRNA levels of
SPARC, alpha 2-type I collagen (COL1A2), matrix metallopro-
teinase-2 (MMP-2) and transforming growth factor-b1 (TGF-b1)
were quantified by SYBRH Green (Invitrogen), using the following
primers: SPARC sense (59-CCACACGTTTCTTTGAGACC-39);
SPARC antisense (59-GATGTCCTGCTCCTTGATGC-39),
COL1A2, 59-CCTACATGGACCAGCAGACTG -3 (forward),
59- GGAGGTCTTGGTGGTTTTGTA -39 (reverse), TGF-b1
59-CCACTCGCTTCTTTGAGACC-39 (forward), 59-TAGTG-
GAAGTGGGTGGGGAC-39 (reverse) and MMP-2 59-CTCA-
GATCCGTGGTGAGAT -3 (forward), 59-AGGCTGGT-
CAGTGGCTTGG-39 (reverse). For qPCR of human samples,
the following primers were used: SPARC, 59-AAACCGAAGAG-
GAGGTGGTG-39 (forward), 59-GCAAAGAAGTGGCAG-
GAAGA-39 (reverse). All PCR amplifications were carried out
using a cycle of 95uC for 10 min and 40 cycles under the following
parameters: 95uC for 30 sec, corresponding melting temperature
for 30 sec, 72uC for 1 min. At the end of the PCR reaction, the
temperature was increased from 60uC to 95uC at a rate of 2uC/
min, and the fluorescence was measured every 15 sec to construct
the melting curve. Values were normalized to levels of glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH; used as housekeep-
ing) transcript (forward 59-CATCTCTGCCCCCTCTGCTG -39;
reverse 59-GCCTGCTTCACCACCTTCTTG-39). Data were
processed by the DDCt method. The relative amount of the
PCR product amplified from untreated cells was set as 1. A non-
template control (NTC) was run in every assay, and all
determinations were performed in triplicate in two or three
separated experiments.
Pathology, Immunofluorescence and
Immunohistochemistry Studies
Some harvested livers were immersed in 10% phosphate-
buffered formalin. Fixed tissue was embedded in paraffin,
sectioned (5 mm) and hematoxylin-eosin (H&E), Masson-trichrome
or Sirius red stained, or used for immunohistochemical analysis of
a-SMA expression. The Knodell score was used to grade the
severity of the necroinflammatory process and fibrosis [18].
Assessments were blinded performed by an experienced pathol-
ogist. For CD4 immunohistochemistry, tissue was embedded in
OCT, cryostat sectioned and fixed for 15 min in alcoholic
formalin. In brief, after tissue dehydration endogenous peroxidase
was blocked with 3% H2O2 in 95% ethanol. Thereafter, sections
were subsequently blocked for endogenous biotin and avidin
(Blocking kit, Vector Laboratories Inc.) and sections were
incubated with the primary antibody anti-CD4 (1:75, 0.2% BSA
in PBS) overnight. After being washed in phosphate-buffered
saline, slides were incubated with peroxidase-linked biotinylated
goat anti-mouse secondary antibody (1:100, Vector Laboratories
Inc.) for 2 h, washed and further incubated with AB complex at
RT. They were then washed twice with PBS and twice with 0.1 M
acetate buffer before incubation with a solution of 3.3-diamino-
benzidine (DAB; Sigma), ammonium nickel sulfate and H2O2 until
signal was developed.
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For immunofluorescence SPARC analysis, mice were perfused
with 4% paraformaldehyde and liver tissue was dissected out, post-
fixed for 90 minutes and subsequently placed in 10 and 20%
sucrose. For SPARC immunofluorescence assay, samples were
embedded in OCT and cryostat sectioned (12 mm). After a 1 hour
incubation in blockage buffer (5% normal donkey serum -Jackson
ImmunoResearch, PA, USA), 1% BSA, 0.3% Triton-X in 16PBS;
room temperature), tissue was incubated with a rat anti-SPARC
monoclonal antibody (1:150, 0.1% BSA, 0.3% Triton-X, 0.02%
sodium azide in PBS; overnight, 4uC; R&D, MN, USA), together
with either rabbit anti-mouse a-SMA (1:75; ab5694, Abcam, MA,
USA) or rabbit anti-Von Willebrand factor (vWF; 1:215; Sigma,
MO, USA) polyclonal antibodies. After extensive washing, tissue
was incubated with Cy3-conjugated donkey anti-rat IgG and
FITC-conjugated donkey anti-rabbit IgG secondary antibodies
(1:450; 1% BSA in PBS, 2 hours, room temperature; Jackson
ImmunoResearch). Images were captured using a Nikon C1 laser
confocal microscope.
For chromogenic immunohistochemical analysis and quantifi-
cation of a-SMA expression, sections were deparaffinized,
rehydrated and heated with buffer citrate (pH = 6) in a microwave
protocol. Endogenous peroxidase was blocked with 3% H2O2 in
95% ethanol. Thereafter, sections were subsequently blocked for
endogenous biotin and avidin (Blocking kit, Vector Laboratories
Inc.), and for unspecific binding of the primary antibody (1% BSA-
PBS). Tissue was then incubated with the rabbit anti-mouse a-
SMA polyclonal antibody (1:100; Abcam). After extensive
washing, slides were incubated with peroxidase-linked biotinylated
goat anti-rabbit secondary antibodies for 2 h, washed and further
incubated with AB complex at RT. They were then washed twice
with PBS and twice with 0.1 M acetate buffer before incubation
with a solution of 3.3-diaminobenzidine (DAB; Sigma), ammoni-
um nickel sulfate and H2O2 until signal was developed. Primary
antibody incubation was omitted in control slides, only rendering a
faint staining (not shown). Quantitative analysis of a-SMA
immunostained area was performed by computerized morpho-
metric analysis (CMA). About 80 light microscope images (200X)
per specimen were captured and analyzed using a color threshold
detection system developed in ImageJ software (NIH, USA).
Results were expressed as percentage of positive area.
Quantification of Hepatic Collagen Content, Collagen
Fibers Maturation and Hyaluronan Deposition
Quantitative analysis of collagen content was performed by
CMA on samples stained with Sirius red. For this purpose,
randomly sampled two hundred light microscope images (200X)
per liver specimen, excepting large centrilobular veins and large
portal tracts ($150 mm) were analyzed. About 80 light microscope
images (200X) per specimen were captured and analyzed using a
color threshold detection system developed in ImageJ (National
Institutes of Health). Values are expressed as percentage of positive
area. To assess the degree of packaging of collagen fibers and their
maturation state, liver sections were examined with polarized light
microscopy using an Olympus BX60 microscope (Olympus,
Tokyo, Japan). Hyaluronan staining was performed as previously
described [19,20].
ELISA Assay of TGF-b1
Total TGF-b1 serum levels after 10 weeks of TAA treatment
were measured by ELISA (R&D systems, Minneapolis, MN,
USA), following manufacturer recommendations. To convert all
latent TGF-b1 to the active form, samples were pretreated with
1 M HCl for 15 min at room temperature. Finally, the reaction
was stopped, by 1 M NaOH neutralization, and the optical density
of each well was determined at 540 or 570 nm.
Microarray Data Analysis
Samples were processed following Affymetrix recommendations
and cRNA was hybridized to the Affymetrix Mouse Gene ST 1.0
array. Both background correction and normalization were done
using RMA (Robust Multichip Average) algorithm [21]. Then, a
filtering process was performed to eliminate low expression probe
sets. Applying the criterion of an expression value greater than 64
in 2 samples for each experimental condition, 18187 probesets
were selected for statistical analysis. R and Bioconductor were
used for preprocessing and statistical analysis. LIMMA (Linear
Models for Microarray Data) [22,23] was used to find out the
probe sets that showed significant differential expression between
experimental conditions. Genes were selected as significant using a
criteria of p-value ,0.01.
Functional and Pathway Analysis
Functional enrichment analysis of Gene Ontology (GO)
categories was carried out using standard hypergeometric test
[24]. The biological knowledge extraction was complemented
through the use of Ingenuity Pathway Analysis (Ingenuity Systems,
www.ingenuity.com), which database includes manually curated
and fully traceable data derived from literature sources.
Transaminases Measurement
Serum alanine (ALT) and aspartate (ALT) transaminases were
measured using an ARCHITECTH (Abbott) autoanalyzer.
Migration Assay
SPARC+/+ and SPARC2/2 mice were sacrificed, spleen were
excised, and single cell suspensions were prepared. Cell suspension
were treated with RBC lysis buffer (0.15 mol/L NH4Cl, 1 mmol/
L KHCO3, 0.1 mmol/L Na2EDTA) and washed with PBS 1%
bovine serum albumin. Then, cells were plated in a plastic petri
dish for 15 min and finally counted and subjected to migration
assay. Migratory capacity to rCCL19 (Peprotech) was assayed
using a 48-Transwell microchemotaxis Boyden Chamber unit
(Neuroprobe, Inc.). In brief, splenocytes (20,000 cells/well) were
placed in the upper chamber of the Transwell unit, which was
separated from the lower chamber by 8 mm pore polycarbonate
filters (Nucleopore membrane, Neuroprobe). rCCL19 (10 ng/ml)
was placed in the lower chamber of the Transwell unit. All the
system units were incubated for 2 h at 37uC in a 5% CO2
humidified atmosphere. After that, the membrane was carefully
removed and cells on the upper side of the membrane were
scraped off with a blade. Cells attached to the lower side of the
membrane were fixed in 2% formaldehyde, and the membranes
from the microchemotaxis Boyden Chamber unit were stained
with 40.6 diamidino-2-phenylindole dihydrochloride (DAPI,
Sigma-Aldrich). Cells were counted using fluorescent-field micros-
copy and a 10x objective lens: the images captured in three
representative visual fields were analyzed using CellProfiler
software (www.cellprofiler.com), and the mean number of cells/
field (SEM was calculated).
Statistical Analysis
Data are expressed as mean 6 SEM when appropriate.
Statistical analysis was performed using Student’s t test or
Mann-Whitney, according to value data distribution. Differences
were considered to be significant when p,0.05.
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Results
Expression of SPARC during Liver Fibrogenesis
We first investigated whether SPARC expression levels may be
upregulated in the liver of cirrhotic patients. To address this issue,
liver biopsies taken from cirrhotic and non-cirrhotic patients were
processed for qPCR studies. A significant upregulation in SPARC
expression levels was observed in cirrhotic samples when
compared to non-fibrotic ones (Figure 1A). These data suggest a
possible role for SPARC in liver fibrogenesis.
We next asked whether or not SPARC expression could be
similarly induced in different in vivo models developed in
SPARC+/+ mice. To address whether SPARC expression levels
may change during liver fibrogenesis, samples were processed for
qPCR studies. SPARC was found to be induced after 2 weeks of
TAA treatment and its expression levels remained similar after 10
weeks of treatment, as well as in mice subjected to BDL
(Figure 1B). While in non-treated animals SPARC expression
was undetectable (Figure 2 B and E), after 10 weeks of TAA
treatment, SPARC was additionally expressed in fibrous septae as
well as in parenchymal areas, surrounding sinusoids (Figure 2H
and K). SPARC was found to be expressed by a-SMA+
myofibroblast cells, mainly within fibrous septae (Figure 2G–I).
In addition, SPARC was also found to be expressed by vWF+
endothelial cells (Figure 2J–and L). A similar expression pattern
was observed in the liver of mice subjected to BDL. SPARC was
expressed by a-SMA+ myofibroblast cells mainly in the portal
areas, but most of the expression was observed in endothelial cells
(Figure 2M–R). From these results we can conclude that SPARC is
overexpressed in the liver of cirrhotic patients and of mice exposed
to different stimuli inducing fibrogenesis.
Decreased Liver Fibrosis and Necroinflammation in
SPARC Deficient Mice
We next decided to investigate whether SPARC deficiency may
influence liver fibrogenesis and processes therein involved. With
this aim, two types of liver fibrosis in vivo models were applied to
SPARC2/2 and in SPARC+/+ mice: chronic TAA application
and bile duct ligation. After 10 weeks of TAA administration,
SPARC+/+ livers showed extensive appearance of portal-portal
and central-portal fibrous septae, regenerative nodules, and
distortion of liver architecture (Figures 3). However, a marked
reduction in the amount of fibrous septae and of regenerative
nodules was found in TAA-treated SPARC2/2 animals
(Figure 3A–F). Similar results were observed in animals subjected
to BDL at 7 days post-surgery: while SPARC+/+ mice developed
prominent fibrous expansions in periportal areas, they were almost
absent in SPARC2/2 animals (Figure 3G–J).
Chronic liver injury and fibrogenesis are intimately linked to
hepatocyte death and inflammation. To further study whether
SPARC deficiency may induce changes in these mechanisms
during liver fibrogenesis, these features were analyzed by an expert
pathologist. A significant reduction in the periportal or periseptal
interface hepatitis, focal necrosis and portal inflammation were
observed in TAA-treated SPARC2/2 when compared to TAA-
treated SPARC+/+ mice (Figure 3A–F and Table 1). All these
differences contributed to the significant reduction in the Knodell
score, frequently used to evaluate necroinflammatory activity,
obtained from SPARC deficient fibrotic liver sections when
compared to wild type fibrotic control tissue (Table 1). Similar
results were obtained in BDL SPARC2/2 mice although the
amount of portal inflammation was similar in comparison with
SPARC+/+ mice.
The present study has shown that there was a significant
increase in aspartate transaminase (AST) and alanine transami-
nase (ALT) levels in SPARC+/+ BDL mice in comparison with
BDL SPARC2/2. No significant differences were observed in
SPARC+/+ and SPARC2/2 mice in TAA groups (Figure 3K)
suggesting that the inflammatory stimuli generated by TAA
intoxication is strong during the first weeks of administration and
correlates with elevated levels of transaminases but not at week 10,
when the fibrotic changes predominate over necrosis of hepato-
cytes.
Figure 1. Induction of SPARC mRNA expression during liver fibrogenesis. (A) Quantitative data showing differences in SPARC mRNA
expression levels in human cirrhotic (Pt#1 to Pt#5) with fibrosis degree F4 and non-cirrhotic liver samples as measured by qPCR. *p,0.05, **p,0.01
compared with healthy liver samples. Mann-Whitney test. (B) qPCR analyses of liver samples from TAA and BDL mice. Complementary DNA was
synthesized and was subjected to qPCR for the expression of SPARC transcripts. The relative amount of the PCR product (AU, arbitrary units) amplified
from control liver samples was set at 1. *p,0.05 versus control (2TAA), **p,0.01 versus control (2BDL), Mann-Whitney test.
doi:10.1371/journal.pone.0054962.g001
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In order to characterize the profile of immune cells in the
hepatic inflammatory infiltrate we performed immunohistochem-
istry for CD4+ T cells and observed that the amount of CD4+ cells
was greatly decreased in SPARC2/2 mice (Figure 4 A–D).
Migration ability towards rCCL19 chemokine was explored in
splenocytes derived from SPARC2/2 and SPARC+/+ mice
in vitro. We observed a reduced migration in SPARC2/2 mice
in response to CCL19 after 2 h of incubation (Figure 4E). Flow
cytometry analysis of splenocytes showed similar expression of
CCR7 receptor (not shown). In agreement with the microarrays
results showing a decreased expression of CCL19 in SPARC2/2
mice (Table 2), qPCR assay confirmed down-regulation of the
transcript (Figure S2).
SPARC Deficient Mice Showed a Decreased Collagen
Deposition
In order to quantify liver content of collagen, the ECM protein
most abundantly accumulated in fibrous septae, tissue sections
from 10 weeks TAA-treated animals were Sirius red stained and
morphometric analysis was thereafter performed. A significant
reduction in Sirius red+ area was found in SPARC2/2 when
compared to SPARC+/+ mice (Figure 5A–B). Consistently, a2(I)
collagen mRNA expression levels were significantly reduced in
SPARC deficient when compared to wild-type animals (3.3160.64
vs. 6.4860.95; SPARC2/2 vs. SPARC+/+) (Figure 5C). Matrix
metalloproteinases (MMPs) are known to be involved in ECM
regulation. We observed that hepatic MMP-2 expression was
significantly increased in SPARC2/2 TAA-treated mice in
comparison with SPARC+/+ (8.1560.42 vs. 3.2560.64, respec-
tively) (Figure 5D).
In accordance with previous results, Sirius red staining on liver
tissue and morphometric analysis obtained from BDL SPARC2/2
mice showed a remarkable decrease in the appearance of collagen
deposits when compared with similarly treated control animals.
While very little Sirius red staining was observed in SPARC
deficient mice, abundant collagen deposits were found within
fibrous expansions in periportal areas as well as in liver
parenchyma of SPARC+/+ mice (Figure 5E–F). Consistent with
Sirius red staining, a2(I) collagen mRNA expression levels were
significantly reduced in SPARC deficient when compared to wild-
type animals (6.0360.67 vs. 10.8661.08; SPARC2/2 vs.
SPARC+/+).
SPARC Deficiency Results in Immature Collagen Fibers
Appearance and Packaging in Fibrotic Livers and in a
Decrease Deposition of Hyaluronic Acid
In SPARC2/2, both TAA and BDL resulted in Sirius red
stained fibers which in most cases could not be observed under
polarized light due to their reduce thickness and immature state: in
this setting they turned into green which make very difficult to
distinguish them from the overall tissue (Figure 6). On the other
hand, most of Sirius red stained collagen fibers observed in TAA
and BDL SPARC+/+ mice could be also observed under polarized
light, due to their increase in thickness and in maturation state: in
this case they became orange to red in color after applying this
procedure.
Hyaluronic acid accumulation in the liver is considered a sign of
advanced liver fibrogenesis [25]. Consistent with previous results,
TAA-treated SPARC+/+ mice livers showed significant deposition
of hyaluronan within fibrous septae while it was almost absent in
TAA-treated SPARC2/2 animals (Figure S1).
Reduced Number of Activated Myofibroblasts in Fibrotic
Livers from SPARC2/2 Mice
Liver fibrogenesis is characterized by trans-differentiation of
different cells into myofibroblasts, including HSCs. HSC-derived
myofibroblasts are known to upregulate their a-SMA expression
levels during the activation process. In order to address whether
either the number of myofibroblasts in fibrous septae and/or the
activation state of myofibroblasts might be affected by SPARC
deficiency, liver tissue obtained from TAA-treated and BDL mice
was immunostained with a-SMA. A significant reduction in the a-
SMA+ immunostained area was found in TAA-treated SPARC2/
2 when compared to TAA-treated SPARC+/+ mice (0.1160.01 vs.
0.4560.02, respectively) (Figure 7A–F and 7I) and in SPARC2/2
subjected to BDL compared to SPARC+/+ mice (0.160.03 vs.
0.760.19, respectively) (Figure 7G–H and 7I). These results
suggest that a reduction in the number of activated myofibroblasts
is likely involved in the inhibition of liver fibrogenesis found in
SPARC deficient mice.
Downregulation of TGF-b1 Hepatic Expression and
Systemic Levels in TAA Treated SPARC Deficient Mice
SPARC is known to be involved in a positive autocrine feedback
loop with TGF-b1, a fibrogenic cytokine with a crucial role in liver
fibrosis. In order to analyze whether SPARC deficiency may cause
downregulation of TGF-b1 expression, its mRNA expression
levels in fibrotic liver from 10 weeks TAA-treated and BDL mice
were measured by qPCR. A significant decrease in the expression
of this cytokine was found in SPARC deficient mice when
compared to control (Figure 7J). To further confirm these results,
serum levels of TGF-b1 were measured by ELISA. Significant
lower levels of TGF-b1 were found in samples obtained from 10
weeks TAA-treated SPARC2/2 when compared to those from
TAA-treated SPARC+/+ mice (Figure 7K). These results suggest
that anti-fibrotic effects of SPARC deficiency are likely partially
mediated by downregulation of TGF-b1 expression levels.
Microarray Analyses Show Changes in Gene Expression
Profile in Naı¨ve SPARC Deficient Mice
In order to explore whether lack of SPARC expression might
influence liver gene expression profile in late fibrogenic processes,
cDNA expression arrays were performed and analyzed (Affymetrix
Mouse Gene ST 1.0 array). To analyze a possible involvement of
basal physiological conditions (‘‘background’’ effects) in the liver of
SPARC deficient or wild-type mice which might partially explain
the differences observed in liver fibrosis models, we have first
compared gene expression profiles among samples of untreated
animals. The genes responsible for basal effect should be found up-
or down- regulated.
A total of 139 upregulated genes (124 known genes and 15 un-
known cDNAs or ESTs) and 155 downregulated genes (138
Figure 2. Patterns of SPARC expression during liver fibrogenesis. (A–F) Representative images taken from SPARC+/+ mice liver sections
stained for SPARC (B, E; red) and SMA (A; green) or vWF (D; green) and merge of both images (C, F). (G–L). Representative images taken from 10 weeks
TAA-treated SPARC+/+ mice liver sections (n = 4–6) stained for SPARC (H, K; red) and SMA (G; green) or vWF (J; green). Co-localization of SPARC and
SMA (I) or SPARC and vWF (L). (M–R) Representative images taken from 7 days BDL SPARC+/+ mice liver stained for SPARC (N, Q; red) and SMA (M;
green) or vWF (P; green). Arrows: co-expression of the two markers; dotted arrows: autofluorescence due to hepatic ceroid-laden macrophages.
Original magnification 400X (A–F) or 1000X (G–R).
doi:10.1371/journal.pone.0054962.g002
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known genes and 17 unknown cDNAs or ESTs) were obtained
(Table S1). To analyze microarray data, three strategies were
followed. Lists of the 10 top upregulated or downregulated gene
lists (Table 2) and gene-interactions networks were performed
(Ingenuity) (Figure 8), and modified genes were classified in
ontological categories (GO, gene ontology) (Table S2). The
analyses of the top up- or down- regulated showed relevant
candidate genes in SPARC2/2 mice compared to SPARC+/+
mice. It is worth to noting that LOXL4, an important protein
involved in the regulation of extracellular matrix components [26],
was found increased while USP2, previously involved in triggering
hepatocyte apoptosis and CCL19, related with inflammation and
fibrogenesis [27,28], were down-regulated in SPARC2/2 untreat-
ed liver tissues when compared to SPARC+/+ mice, likely
suggesting an initial condition of liver cells which would make
them less susceptible to death and compatible with a subsequent
reduction in fibrosis development.
Ingenuity Pathway Analysis (IPA) analyses (p,0.01) suggested
several gene networks which likely involve protective mechanisms
of SPARC deficiency against liver fibrogenesis. The network with
the highest score and biological significance was chosen
(Figure 8A). In this model, lack of SPARC expression was found
related to Sox9 expression. Thus, Sox9 (sex determining region Y-
box 9) and CDH1 (Cadherin-1 or E-cadherin; with a gene
expression activity regulated by and known to be able to bind to
Sox9) were found up-regulated in the liver of SPARC2/2 mice. In
addition, other genes showing increased expression levels in these
mice within the same gene interaction network were cldn1 (claudin
1), secretase gamma, aph1b (anterior pharynx defective 1b
homolog), pag1 (phosphoprotein associated with glycosphingolipid
microdomains 1), mpzl1 (myelin protein zero-like 1) and agk
(acylglycerol kinase). In addition, lack of SPARC expression was
found related to a down-regulation in PCGF2 (polycomb group
ring finger), a factor that maintains repression of genes related to
tumorigenesis and cell cycle [29]. In turn, PCGF2 likely interacts
with UBE2U (ubiquitin-conjugating enzyme E2U), involved in
ubiquitination, found upregulated in SPARC2/2 mice. Consis-
tently, other proteins able to interact with UBE2U, such as two
members of the TRIM (tripartite motif-containing) family and
MID2 (midline 2), were also found upregulated upon SPARC
deficiency.
Interestingly, the GO analysis revealed statistically enriched
ontological categories including those related in chromatin
remodeling, cAMP signaling or cell cycle regulation. A complete
list of all genes included in each GO category is given as
supplementary information. Overall our data suggest that the liver
of SPARC deficient animals have a gene expression profile which
likely makes them less susceptible to develop liver fibrosis.
Microarray Analyses Show Changes in Gene Expression
Pattern in Advanced Liver Fibrogenesis due to SPARC
Deficiency
To uncover new protective mechanisms involved in the
observed reduction in the degree of liver fibrosis observed in
SPARC deficient mice, cDNA expression array analyses were
performed comparing liver tissue samples obtained from
SPARC2/2 and SPARC+/+ mice after 10 weeks of TAA
administration. A total of 492 genes showed a p,0.01 (281
upregulated and 211 downregulated genes) in SPARC2/2 mice.
Top up-regulated and down-regulated genes are shown in Table 2.
They include upregulation of CLDN4 (Claudin 4), a component of
the tight junction strands, and downregulation of CIDEC (cell
death-inducing DNA fragmentation factor-a-like effector C), a
potent apoptosis inducer [30]. Interestingly, canonical pathway
and biological functions identified by IPA showed a large group of
upregulated genes associated with DNA repair and detoxification.
Remarkably a large group of interacting genes were found
upregulated (Figure 8B) in the context of SPARC deficiency
including at the center of the network those encoding ATM (ataxia
telangiectasia-mutated) kinase [31] and the transcription factors
BRCA (breast cancer) 1 [32], BRCA2 [33] and BARD1 (BRCA1-
associated RING domain) [34] and including effector genes such
as topbp1 (topoisomerase (DNA) II binding protein 1) [31], rrm1
(ribonucleotide reductase M1) [35], brip1 (BRCA1 interacting
protein C-terminal helicase 1) [36], pole1 (polymerase (DNA
directed), epsilon, catalytic subunit) and 2 (polymerase (DNA
directed), epsilon 2, accessory subunit) [37], msh2 (mutS homolog
2, colon cancer, nonpolyposis type 1 (E. coli) [38], mbd4 (methyl-
CpG binding domain protein 4) [39], blm (Bloom syndrome,
RecQ helicase-like) [38], fancb (Fanconi anemia, complementa-
tion group B) [40], rfc4 (replication factor C (activator 1) 4) [37],
Figure 3. Reduced liver damage in SPARC deficient mice. (A–F) Representative photomicrographs of liver sections from untreated SPARC+/+
(A) or 10 weeks TAA-treated SPARC+/+ or SPARC2/2 mice (n = 6–8), stained with H&E (A–C) or Masson’s trichrome (D–F). (G–J) Representative
photomicrographs of liver sections from SPARC+/+ and SPARC2/2 mice subjected to BDL, stained with H&E (G–H) or Masson’s trichrome (I–J). Original
magnification 200X. PT, portal tract; CV, central vein. (K) Serum ALT and AST levels were measured at the indicated time in TAA-treated and BDL mice.
Dotted lines, upper normal limited. **p,0.05 versus treated SPARC+/+.
doi:10.1371/journal.pone.0054962.g003
Table 1. Severity of necroinflamatory activity and fibrosis in SPARC+/+ and SPARC2/2 mice after 10 weeks of TAA treatment (n
= 6–8) or in SPARC+/+ and SPARC2/2 BDL mice (n = 5–6).
SPARC+/+ SPARC2/2 SPARC+/+ SPARC2/2
TAA 10 weeks TAA 10 weeks BDL 7 days BDL 7 days
Periportal or Periseptal Interface hepatitis 2.760.5 1.360.4* 1.660.5 0.6260.2
Focal (spotty) lytic necrosis, focal necrosis, apoptosis and focal inflammation 461.4 2.360.5* 3.560.3 0.7560.25*
Portal inflammation 2.560.6 1.1660.9* 260.0 1.560.3
Fibrosis 3.760.5 2.560.5* 2.660.2 0.560.0*
Knodell score 13.2561.2 7.3361.5* 9.7560.5 3.2560.3*
*p,0.05.
doi:10.1371/journal.pone.0054962.t001
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chaf1A (chromatin assembly factor 1, subunit A (p150) and B
(chromatin assembly factor 1, subunit B (p60)) [41], Hist1H3A
(histone cluster 1, H3a) and hat1 (histone acetyltransferase 1) [42].
Consistently, E2F, able to induce gene expression of many
transcriptional factors and effectors in DNA repair and stability
pathways including some of the most relevant ones mentioned
above [43], was found upregulated at the center of the second
most relevant IPA gene network map, as well as other related
functional proteins such as PCNA (proliferating cell nuclear
antigen), MCM2 (minichromosome maintenance deficient 2
mitotin), MCM3, MCM4 (minichromosome maintenance defi-
cient 4 homolog), MCM6, MCM7, RPA2 (replication protein A2),
Figure 4. Reduced hepatic inflammatory infiltration and migratory capacity in SPARC deficient mice. Photomicrographs of
representative liver sections from TAA-treated animals. SPARC+/+ mice showed an increased CD4+ cells infiltration in hepatic parenchyma, especially
around portal tracts (A,B); while in TAA-treated SPARC2/2 mice CD4+ cells are scarce and located near the sinusoids (C,D). Arrows indicate CD4+ cells.
Original magnification 400X. (E) Migratory response of splenocytes towards CCL19 chemokine. Percentage of cells that migrated relative to respective
controls for SPARC+/+ and SPARC2/2 splenocytes (n = 3 replicates) in a Boyden Chamber system. Splenocytes were placed into the upper well,
separated from the lower by a 5-mm porosity membrane. The bottom well contained either DMEM or DMEM with 10 ng/ml rCCL19 and cells were
allowed to migrate during 2 h. ***p,0.001, Mann Whitney test.
doi:10.1371/journal.pone.0054962.g004
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PRIM1 (DNA primase, p49 subunit), PRIM2 (A primase, p58
subunit), CDT1 (chromatin licensing and DNA replication factor
1) and ASF1B (ASF1 anti-silencing function 1 homolog B); not
shown). It is worth noting that the first and most significant gene
network model showed an upregulation of ABCC4 (ATP-binding
cassette sub-family C member 4), a key ABC transporter involved
in the removal of chemicals, xenobiotics and products of oxidative
stress [44], and the downregulation of TRIM25 (tripartite motif-
containing 25) [45] and CTSF (cathepsin F) [46] involved in
protein degradation processes.
Discussion
SPARC expression is known to be induced during liver
fibrogenesis in different species. In mouse, SPARC upregulation
has only been reported in a schistosomiasis model of liver fibrosis
[6]. In this work, we confirmed this result in two additional models
of this disease caused by different etiologies: hepatotoxicity
mediated by chronic TAA intoxication, and cholestasis induced
by BDL. In addition, we provide new evidence, based on a genetic
in vivo model, showing that SPARC, expressed by HSC and
endothelial cells, is involved in liver fibrogenesis. Moreover, our
data support that SPARC plays a major role in key pathogenic
events related to the fibrogenic process such as hepatocyte
necrosis, inflammation and recruitment/activation of myofibro-
blasts as well as in the induction of the profibrogenic cytokine
TGF-b1. These findings are consistent with previous reports,
based on studies performed with other tissues, showing SPARC
involvement in proinflammatory and profibrogenic mechanisms
[47,48]. Our gene expression profile analyses suggest that SPARC
upregulation in the fibrotic liver might induce deficiencies in DNA
repair mechanisms likely resulting in enhanced liver cell death and
subsequent increased ECM deposition as a consequence of scar
formation process. Overall, our data strongly support that SPARC
plays a prominent profibrogenic role in the context of chronic liver
injures, providing new clues to understand mechanisms therein
involved. Although gene targeting is a powerful tool for the study
of a disease on a uniform genetic background, the gene knockout
approach must be used with caution, particularly in interpretations
of the phenotypes that are obtained in liver biology, where many
genes have pleiotropic functions.
Myofibroblasts do normally accumulate in the parenchyma
close to liver injured areas. Many of them most likely derive from
resident HSCs, the main source of fibrillar collagen and the major
targets of anti-fibrotic therapies [49]. By mean of immunohisto-
Table 2. IPAH top molecules which were significantly alters in
SPARC2/2 versus SPARC+/+ mice and those modified in
SPARC2/2 versus SPARC+/+10 weeks TAA treated mice.
IPAH Top Molecules. Background
Fold change up-regulated
Gene ID Exponential Value
NIPAL1 NM_001081205 1,975
ACCN5 NM_021370 1,608
PIK3C2G NM_207683 1,561
LOXL4 NM_001164311 1,514
SLC34A2 NM_011402 1,232
C17orf78 NM_001037932 1,230
UBE2U NM_001033773 1,171
NDRG1 NM_008681 1,118
THEM5 NM_025416 1,117
FOXQ1 NM_008239 1,102
Fold change down-regulated
Gene ID Exponential Value
SPARC NM_009242 24,051
C1orf51 BC132471 22,245
USP2 NM_198092 21,994
CCL19 NM_011888 21,544
TSKU NM_001168541 21,508
CABYR NM_027687 21,338
PPIH NM_001110130 21,335
PER2 NM_011066 21,120
P2RY2 NM_008773 20,984
SYDE2 NM_001166064 20,892
IPAH Top Molecules. Ten Weeks of TAA Treatment
Fold change up-regulated
Gene ID Exponential Value
NPY NM_023456 2,092
CYP1A1 NM_009992 2,053
1600029D21Rik NM_029639 2,028
Sprr1a NM_009264 1,615
SLC7A11 NM_011990 1,498
CLDN4 NM_009903 1,487
ARG2 (includes EG:11847) NM_009705 1,471
MCM6 NM_008567 1,449
TMC5 NM_001105252 1,358
TMEM45A NM_019631 1,287
Fold change down-regulated
Gene ID Exponential Value
SPARC NM_009242 24,517
UBLCP1 NM_024475 22,273
CIDEC NM_178373 21,723
Table 2. Cont.
IPAH Top Molecules. Background
Fold change up-regulated
Gene ID Exponential Value
AKR1C3 NM_134066 21,659
ACOT2 NM_134188 21,637
CHRNA2 NM_144803 21,223
SLC22A5 NM_011396 21,097
CYP8B1 NM_010012 21,022
CPT1B NM_009948 21,002
LYVE1 NM_053247 20,965
doi:10.1371/journal.pone.0054962.t002
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chemical studies, a decrease in the number of a-SMA+ myofibro-
blasts was observed in fibrotic livers of SPARC deficient mice.
This finding is consistent with our recently published data showing
that specific SPARC knock-down in activated HSCs reduces their
migratory ability as well as their activation state [50]. Thus, the
induction of SPARC expression in activated HSCs likely promotes
their accumulation in chronically injured liver areas further
aggravating the pathologic state. Whether SPARC may or not
participate in the activation/proliferation of other non-parenchy-
mal cells such as Kupffer, endothelial or biliary epithelial cells in
response to chronic injury is unknown and merits further
investigation.
In addition, recent studies demonstrated that SPARC is able to
exert potent stimulatory effects on TGF-b1 expression in cultured
HSCs [5], skin and lung fibroblasts, and mesangial cells [4,15,51].
In agreement with this, it is worth noting that in these studies
lower levels of TGF-b1 were found in fibrotic livers and in serum
samples from TAA-treated SPARC deficient mice when compared
to wild-type counterparts. Therefore, and in the context of fibrotic
diseases, these data further emphasizes the prevailing hypothesis of
TGF-b1 expression being dependent on local SPARC expression
levels. Based on the abundant literature related to the function of
TGF-b1 in fibrogenesis [52] we hypothesize that this mechanism
likely explain most of the observed phenotype.
Collagen fibrillar formation is a critical step in fibrogenesis and
SPARC is a well-known collagen-binding matricellular protein
with a reported role in type I collagen packaging. Thus by mean of
in vitro studies, Rentz et al. have shown that collagen I produced by
SPARC2/2 cells was not efficiently incorporated into detergent-
insoluble fractions [53]. In agreement with this, we herein show
that fibrotic livers obtained from SPARC deficient mice contain
thin, dispersed and predominantly immature collagen fibers while
Figure 5. Reduced liver fibrosis in SPARC deficient mice. (A) Representative photomicrographs of liver sections stained with picrosirius red.
SPARC+/+ mice show staining limited to periportal areas (left panel), while liver sections from TAA-treated SPARC+/+ mice exhibits marked portal
fibrosis and portal-portal bridges (central panel) and those from TAA-treated SPARC2/2 mice present weak fibrotic response (right panel). (B)
Morphometric quantification of Sirius red stained area showing a significant attenuation of the fibrotic process in TAA-treated SPARC2/2 mice when
compared to treated wild-type mice. **p,0.01, Mann-Whitney test. (C–D) Quantitative data from qPCR analysis of collagen (COL1A2) and MMP-2
mRNA expression. *p,0.05, **p,0.01 versus SPARC+/+ TAA 10 weeks, Mann-Whitney test. (E) Representative pictures taken from liver sections of
from SPARC+/+ or SPARC2/2 mice, at 7 days after BDL. Original magnification 200X. PT, portal tract; CV, central vein. (F) Morphometric quantification
of Sirius red stained area showing a significant attenuation of the fibrotic process in SPARC2/2 mice at day 7 after BDL when compared to wild-type
mice. **p,0.01, Mann-Whitney test. (G) qPCR analysis of collagen mRNA expression in SPARC+/+ and SPARC2/2 mice subjected to BDL. *p,0.05,
versus BDL SPARC+/+ Mann-Whitney test.
doi:10.1371/journal.pone.0054962.g005
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they were thick, highly compacted and mature in those from
SPARC+/+ animals. Therefore, our data are consistent with
previous reports on SPARC function in the context of collagen
fiber maturation and compaction [54]. Little information is
available on the role of SPARC in human liver fibrosis: we
(herein) and others [7] showed that SPARC is overexpressed in the
liver of cirrhotic patients. Nevertheless, these new data obtained
from a mouse genetic model, using different in vivo disease models,
are consistent with a profibrogenic role of SPARC in the context
of chronic liver disease. Moreover, SPARC is shown to likely
mediate key events in liver fibrogenesis such as liver inflammation,
induction of TGF-b1 expression levels and the accumulation of
active myofibroblasts.
Matrix metalloproteinase-2 (MMP-2), a type IV collagenase, is
upregulated in chronic liver disease and is considered a profibrotic
factor [55]. However, recent evidence in in vivo animal models
revealed that MMP-2 deficiency is associated with increased
hepatic collagen type I expression and fibrogenesis [56]. In
agreement with these results, we observed that MMP-2 messenger
RNA was increased at week 10 of TAA treatment in SPARC2/2
mice. In addition, our microarray analysis also demonstrated that
MMP-2 is significantly increased in SPARC2/2 TAA-treated
mice (not shown), suggesting that this effect may be involved, at
least in part, in the protective effect of SPARC knock-down on
liver fibrogenesis.
In an effort to identify changes in gene expression profile, which
could explain the observed protective mechanisms against TAA
Figure 6. Reduced maturation of SPARC2/2 collagen fiber deposits. Representative pictures showing picrosirius red stained liver sections
obtained from SPARC+/+ (A,C,E) or SPARC2/2 (B,D,F) mice (n = 6–8) observed under polarized light. Animals were left untreated (A,B), or were TAA-
treated during 10 weeks (C,D) or subjected to BDL (E, F). Note the predominant mature and compacted nature of collagen fibers in wild-type treated
mice and their immature and thin appearance in SPARC2/2 animals. Original magnification 400X.
doi:10.1371/journal.pone.0054962.g006
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damage in SPARC2/2 mice in an established model of liver
fibrosis, microarray analyses were performed. A number of genes
were narrowed down; nevertheless, a number of candidates
showed a significant difference in expression when comparing
SPARC knockout and wild-type mice. Our overall results suggest
that the reduction in liver fibrogenesis observed in SPARC
deficient mice seems to be the result of a sum of several
mechanisms rather than the effect of changes in a small group
of specific genes. Accordingly to this, we chose the approach of
comparing ingenuity networks rather than analyzing changes in
individual gene expression.
Interestingly, the list of top modified genes in untreated mice
showed differential regulation of certain gene categories which
might partially explain a protective status against any insult as a
result of SPARC deficiency: the specific involvement of several of
these genes in liver pathologies will be analyzed in our future
research. A candidate gene would be LOXL4, a target of TGF-b1
[26] found to cause reduction in TGFb1-mediated cell motility of
Figure 7. Reduction in the number of active myofibroblasts and in liver and serum TGF-b1 levels in SPARC deficient fibrotic mice.
(A–H) Representative pictures taken from liver sections of untreated SPARC+/+ and SPARC2/2 (A,B), 10 weeks TAA treated SPARC+/+ (C,E) andSPARC2/2
(D,F), or BDL SPARC+/+ (G) and SPARC2/2 (H) mice immunostained for a-SMA. (E,F) are higher magnification images from box areas in C,D respectively. (I)
Quantitative data of densitometric analyses of aSMA immunostained area from TAA-treated and BDL SPARC2/2 or SPARC+/+ mice. **p,0.01, Mann-
Whitney test. (J) Quantitative data of TGF-b1mRNA levels obtained by qPCR analysis from 10weeks TAA-treated and BDL SPARC+/+ or SPARC2/2mice (n
= 6–8). Data are expressed as relative values to those of wild-type mice without treatment. *p,0.05, SPARC+/+ treated vs SPARC2/2 treated. Mann-
Whitney test. (K) Serum levels of TGF-b1 were measured after 10 weeks of TAA treatment. nd, non-detectable. **p,0.01, Mann-Whitney test.
doi:10.1371/journal.pone.0054962.g007
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hepatoma cells. In addition, USP2 was found down-regulated in
SPARC2/2 mice likely rendering hepatocytes less susceptible to
TNF-mediated apoptosis [57]. Another top down-regulated gene
was CCL19, a chemokine known to attract dendritic cells and
lymphocytes [58,59,60] which might be involved in the reduction
of inflammation observed in SPARC deficient mice after TAA
treatment. However, no significant differences were observed in
CCL19 gene expression at week 10 of TAA administration leading
us to speculate that low expression levels of CCL19 in null mice at
the beginning of the injury with TAA could be critical for the
subsequent generation of inflammation, necrosis of hepatocytes
and fibrogenesis. The magnitude of inflammatory infiltrates was
markedly reduced in SPARC2/2 mice, especially CD4+ cells, and
the decreased migratory capacity of their splenocytes towards
CCL19 chemokine in vitro leading us to speculate that the
decreased fibrosis observed in these animals could be mediated,
at least in part, by lessening of an inflammatory effect. This
observation was not confirmed in BDL model. These results are in
agreement with Rempel et al. who consider that that SPARC2/2
mice have an impaired immune system [61].
Furthermore, CCL19 receptor is expressed in HSCs and its
activation was previously shown to induce its migration capacity
[62] a relevant feature involved in liver fibrogenesis [63]. Upon
TAA long-term treatment, CIDEC, a known potent inducer of
apoptosis [30,64], is among the top down-regulated genes in
SPARC deficient mice, likely cross-linking altered metabolism
with programmed cell death in the TAA-induced fibrosis model.
Using the IPA tool we were able to find highly significant
networks and pathways likely involved in the described functional
phenotype. In fact, naı¨ve SPARC2/2 and SPARC+/+ mice seem
to significantly differ in their gene expression profiles. As
previously discussed, a positive feedback between SPARC and
TGF-b1 was experimentally established; in addition, it is
speculated that SPARC might regulate the signaling pathway
induced by TGF-b1 [65]. Our best IPA gene network model
showed that SPARC depletion was associated with an increased in
SOX9 expression levels, likely mediated by TGF-b1 signaling
pathway. SOX9 is a transcription factor involved in liver
development, shown to contribute to hepatic physiology preser-
vation [66]. However, a previous work suggested that SOX9 has a
role as a transcriptional regulator in fibrogenesis promoting
extracellular matrix deposition [67].
Additionally, the shown network establishes a relationship with
CDYL and EHMT1 genes, codifying for histone methylases and
acetylases likely involved in SOX9 gene regulatory function.
Furthermore, in our network model SOX9 is shown to interact
and to induce E-cadherin gene expression, also found upregulated
in the liver of naı¨ve SPARC deficient mice. E-cadherin is an
important epithelial cell-cell adhesion protein considered as a
marker of non-activated HSCs [68]. Claudin 1, a tight junction
protein, is another adhesion protein also found overexpressed in
SPARC null mice and known to interact and mutually activate
each other with E-cadherin. Tight junctions are confined to
epithelial cells, forming continuous belts around cells and serving
as a physical barrier to regulate transport through the paracellular
space. Another important event shown in the gene network model
is the decrease of CCL19 in SPARC2/2 mice, likely involved in
the observed reduction in lymphocyte recruitment and process of
liver inflammation which normally characterizes liver fibrosis as
previously discussed. In turn, the decrease in CCL19 gene activity
Figure 8. The top network of differentially expressed genes. The networks are presented as graphical displays where genes appear as nodes
and the molecular relationships are represented by lines. Up-regulated and down-regulated genes in SPARC2/2 mice are shown as red spot or green
spot, respectively. The top network of differentially expressed genes in SPARC2/2 versus SPARC+/+ mice (A) or SPARC2/2 after 10 weeks of TAA
treatment versus SPARC+/+ TAA treated mice (B), as identified by IPA analysis. Intensity of the red or green color shows the level of gene expression.
Gray represents a gene found which is related to the others but did not meet the cutoff criteria. A Activation, E Expression (includes metabolism/
synthesis for chemicals), I Inhibition, L Proteolysis (includes degradation for Chemicals), LO Localization, M Biochemical Modification, MB Group/
complex Membership, P Phosphorylation/Dephosphorylation, PD Protein-DNA binding, PP Protein-Protein binding, RB Regulation of Binding,T
Transcription,TR Translocation.
doi:10.1371/journal.pone.0054962.g008
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is related with several transcriptional repressor and stress response
factors (such as HSF4, ZHX2), linked to ERK1/2 pathway, also
found down-regulated. SPARC2/2 mice have an increased in
secretase gamma (protease complex) and its protein complex
partner APH1B, as well as PAG1 (a protein shown to be
phosphorylated by secretase gamma), likely involving Notch
signaling pathway-related changes. Secretase gamma and PAG1
might be also involved in the regulation of T cell activation.
Overall our results support the concept of basal conditions in the
context of SPARC deficiency making the liver less susceptible to
external insults such as those causing liver fibrosis.
In addition to the influence of a basal phenotype condition, the
results of pathway analyses on samples obtained from TAA treated
animals suggest that SPARC deficient mice have a more intact or
better established machinery to repair DNA or detoxify the body
from external chemical stimuli as suggested by the remarkable
upregulation in genes such as ATM, BRCA1, BRCA2 and
BARD1. ATM is a sensor of DNA damage and phosphorylates
p53 (tumor suppressor, which can activate apoptosis and arrest the
cell cycle if DNA damage is not resolved) [69]. Additionally, ATM
knockout affects cell survival and liver regeneration [70].
Consistently, BRCA1 complexed with BARD1 has tumor
suppression properties and is involved on protein ubiquitination
for degradation. Moreover, it needs to form a complex with
BRCA2, also herein upregulated, to repair damaged DNA. It is
reported that TGFb1/Smad3 counteracts BRCA1-mediated
DNA repair [71] and expression [72]. Our results on upregulation
in BRCA1 as well as in its related partners and effectors involved
in DNA repair are consistent with the decreased in TGF-b1 levels
found in our study. Via PI3K, ATM likely up-regulates ABCC4, a
key ABC transporter involved in the removal of chemicals,
xenobiotics and products of oxidative stress, as well as the efflux of
GSH and bile salts through the basolateral membrane of
hepatocytes [73]. Exported GSH may be mediating protection
against oxidative damage in the tissue. It was previously reported
that the expression and localization of this transporter in
centrilobular hepatocytes was increase in mice receiving hepato-
toxic doses of acetaminophen or CCl4 [74], which correlates with
protection against further doses of acetaminophen [75]. Therefore,
upregulation in the expression of ATM and of its related BCRA
transcriptional factor complex components as well as of their
specific effectors suggest the establishment of a more efficient
machinery mounted to repair DNA defects likely resulting in less
susceptibility to liver cell apoptosis. Such mechanisms together to
detoxifying activities mediated by ABCC4 might explain the
reduction in liver damage and subsequent fibrosis observed in
SPARC deficient mice.
In summary, we herein show that SPARC depletion in a mouse
genetic model results in protection against liver fibrosis develop-
ment. Mechanisms therein involved are complex and likely act at
different levels and through diverse processes implicated in
fibrogenesis. Thus, our new evidences implicate reduction in the
extent of liver inflammation, in TGF-b1 expression levels (a master
molecule involved in the ECM deposition) and in the activation
status of HSCs, and an increase in MMP2 expression. In addition,
they suggest the establishment of a transcriptional activation of the
DNA repair machinery making liver cells less susceptible to
apoptosis thus likely preventing liver damage. Overall, giving the
complexity of advanced liver fibrosis it is believed that therapeutic
avenues need also to act at different parallel mechanisms to be
efficient in ameliorating disease mechanisms. These studies further
support a beneficial effect of SPARC downregulation and suggest
that this might be a good candidate for an in vivo approach using
gene therapy tools (e.g. long-term expression vectors) for future
antifibrotic therapeutic actions.
Supporting Information
Figure S1 SPARC deficiency shows decrease deposition
of hyaluronic acid. Representative pictures taken from liver
sections of TAA untreated (A, B) or 10 weeks TAA treated
SPARC+/+ (C) or SPARC2/2 (D) mice stained for hyaluronic acid
(n = 6–8). Original magnification 100X. PT, portal tract; CV,
central vein.
(TIF)
Figure S2 qPCR analysis for selected microarray genes.
mRNA expression levels in liver samples of SPARC+/+ and
SPARC2/2 mice, untreated or treated 10 weeks with TAA, of: (A)
CCL19, (B) Brca1, (C) ABCC4F, (D) Cldn1, (E) ATMF, (F) Cdh1,
(G) Bard1. Values were normalized to levels of GAPDH transcript.
Error bars represent SD values. p values are presented in the
figure.
(TIF)
Table S1 List of the significantly upregulated and
downregulated genes between SPARC2/2 and SPARC+/+,
6 weeksTAA treated SPARC+/+ andTAA treated SPARC2/2,
10 weeks TAA treated SPARC+/+ and TAA treated
SPARC2/2.
(XLSX)
Table S2 List of the significantly modified gene classi-
fied by ontological categories.
(XLS)
Acknowledgments
We would like to thank Soledad Arregui, Guillermo Gasto´n and Juan
Politti for expert technical assistance, and Dr. Alejandra Camino, for
advice.
Author Contributions
Conceived and designed the experiments: GM JA CA. Performed the
experiments: CA EP NK MM LA MG FC EG EF JB GM FP. Analyzed
the data: GM RB OP FC. Wrote the paper: CA JA EP GM.
References
1. Bradshaw AD, Sage EH (2001) SPARC, a matricellular protein that functions in
cellular differentiation and tissue response to injury. J Clin Invest 107: 1049–
1054.
2. Brekken RA, Sage EH (2000) SPARC, a matricellular protein: at the crossroads
of cell-matrix. Matrix Biol 19: 569–580.
3. Francki A, Bradshaw AD, Bassuk JA, Howe CC, Couser WG, et al. (1999)
SPARC regulates the expression of collagen type I and transforming growth
factor-beta1 in mesangial cells. J Biol Chem 274: 32145–32152.
4. Wang JC, Lai S, Guo X, Zhang X, de Crombrugghe B, et al. (2010) Attenuation
of fibrosis in vitro and in vivo with SPARC siRNA. Arthritis Res Ther 12:
R60.
5. Camino AM, Atorrasagasti C, Maccio D, Prada F, Salvatierra E, et al. (2008)
Adenovirus-mediated inhibition of SPARC attenuates liver fibrosis in rats.
J Gene Med 10: 993–1004.
6. Frizell E, Liu SL, Abraham A, Ozaki I, Eghbali M, et al. (1995) Expression of
SPARC in normal and fibrotic livers. Hepatology 21: 847–854.
7. Blazejewski S, Le Bail B, Boussarie L, Blanc JF, Malaval L, et al. (1997)
Osteonectin (SPARC) expression in human liver and in cultured human liver
myofibroblasts. Am J Pathol 151: 651–657.
8. Lamireau T, Le Bail B, Boussarie L, Fabre M, Vergnes P, et al. (1999)
Expression of collagens type I and IV, osteonectin and transforming growth
factor beta-1 (TGFbeta1) in biliary atresia and paucity of intrahepatic bile ducts
during infancy. J Hepatol 31: 248–255.
Lack of SPARC Ameliorates Hepatic Fibrosis in Mice
PLOS ONE | www.plosone.org 15 February 2013 | Volume 8 | Issue 2 | e54962
9. Le Bail B, Faouzi S, Boussarie L, Guirouilh J, Blanc JF, et al. (1999)
Osteonectin/SPARC is overexpressed in human hepatocellular carcinoma.
J Pathol 189: 46–52.
10. Goldenberg D, Ayesh S, Schneider T, Pappo O, Jurim O, et al. (2002) Analysis
of differentially expressed genes in hepatocellular carcinoma using cDNA arrays.
Mol Carcinog 33: 113–124.
11. Lau CP, Poon RT, Cheung ST, Yu WC, Fan ST (2006) SPARC and Hevin
expression correlate with tumour angiogenesis in hepatocellular carcinoma.
J Pathol 210: 459–468.
12. Gressner AM, Weiskirchen R (2006) Modern pathogenetic concepts of liver
fibrosis suggest stellate cells and TGF-beta as major players and therapeutic
targets. J Cell Mol Med 10: 76–99.
13. George J, Roulot D, Koteliansky VE, Bissell DM (1999) In vivo inhibition of rat
stellate cell activation by soluble transforming growth factor beta type II
receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci U S A
96: 12719–12724.
14. Qi Z, Atsuchi N, Ooshima A, Takeshita A, Ueno H (1999) Blockade of type beta
transforming growth factor signaling prevents liver fibrosis and dysfunction in
the rat. Proc Natl Acad Sci U S A 96: 2345–2349.
15. Wrana JL, Overall CM, Sodek J (1991) Regulation of the expression of a
secreted acidic protein rich in cysteine (SPARC) in human fibroblasts by
transforming growth factor beta. Comparison of transcriptional and post-
transcriptional control with fibronectin and type I collagen. Eur J Biochem 197:
519–528.
16. Muller A, Machnik F, Zimmermann T, Schubert H (1988) Thioacetamide-
induced cirrhosis-like liver lesions in rats–usefulness and reliability of this animal
model. Exp Pathol 34: 229–236.
17. Oren R, Dotan I, Papa M, Marravi Y, Aeed H, et al. (1996) Inhibition of
experimentally induced cirrhosis in rats by hypothyroidism. Hepatology 24:
419–423.
18. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, et al. (1981) Formulation
and application of a numerical scoring system for assessing histological activity in
asymptomatic chronic active hepatitis. Hepatology 1: 431–435.
19. Jameson JM, Cauvi G, Sharp LL, Witherden DA, Havran WL (2005)
Gammadelta T cell-induced hyaluronan production by epithelial cells regulates
inflammation. J Exp Med 201: 1269–1279.
20. Piccioni F, Malvicini M, Garcia MG, Rodriguez A, Atorrasagasti C, et al. (2012)
Antitumor effects of hyaluronic acid inhibitor 4-methylumbelliferone in an
orthotopic hepatocellular carcinoma model in mice. Glycobiology 22: 400–410.
21. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, et al. (2003) Summaries
of Affymetrix GeneChip probe level data. Nucleic Acids Res 31: e15.
22. Smyth GK (2004) Linear models and empirical bayes methods for assessing
differential expression in microarray experiments. Stat Appl Genet Mol Biol 3:
Article3.
23. Gentleman R (2005) Bioinformatics and computational biology solutions using
R and Bioconductor: Springer Verlag.
24. Draghici S, Dra˘ghici S (2003) Data analysis tools for DNA microarrays: CRC
Press.
25. George J, Tsutsumi M, Takase S (2004) Expression of hyaluronic acid in N-
nitrosodimethylamine induced hepatic fibrosis in rats. Int J Biochem Cell Biol
36: 307–319.
26. Kim DJ, Lee DC, Yang SJ, Lee JJ, Bae EM, et al. (2008) Lysyl oxidase like 4, a
novel target gene of TGF-beta1 signaling, can negatively regulate TGF-beta1-
induced cell motility in PLC/PRF/5 hepatoma cells. Biochem Biophys Res
Commun 373: 521–527.
27. Grant AJ, Goddard S, Ahmed-Choudhury J, Reynolds G, Jackson DG, et al.
(2002) Hepatic expression of secondary lymphoid chemokine (CCL21) promotes
the development of portal-associated lymphoid tissue in chronic inflammatory
liver disease. Am J Pathol 160: 1445–1455.
28. Marra F (2002) Chemokines in liver inflammation and fibrosis. Front Biosci 7:
d1899–1914.
29. Kanno M, Hasegawa M, Ishida A, Isono K, Taniguchi M (1995) mel-18, a
Polycomb group-related mammalian gene, encodes a transcriptional negative
regulator with tumor suppressive activity. EMBO J 14: 5672–5678.
30. Tang X, Xing Z, Tang H, Liang L, Zhao M (2011) Human cell-death-inducing
DFF45-like effector C induces apoptosis via caspase-8. Acta Biochim Biophys
Sin (Shanghai) 43: 779–786.
31. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S (2004) Molecular
mechanisms of mammalian DNA repair and the DNA damage checkpoints.
Annu Rev Biochem 73: 39–85.
32. Moynahan ME, Chiu JW, Koller BH, Jasin M (1999) Brca1 controls homology-
directed DNA repair. Mol Cell 4: 511–518.
33. Patel KJ, Yu VP, Lee H, Corcoran A, Thistlethwaite FC, et al. (1998)
Involvement of Brca2 in DNA repair. Mol Cell 1: 347–357.
34. Boulton SJ, Martin JS, Polanowska J, Hill DE, Gartner A, et al. (2004) BRCA1/
BARD1 orthologs required for DNA repair in Caenorhabditis elegans. Curr Biol
14: 33–39.
35. Zheng Z, Chen T, Li X, Haura E, Sharma A, et al. (2007) DNA synthesis and
repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356: 800–808.
36. Bridge WL, Vandenberg CJ, Franklin RJ, Hiom K (2005) The BRIP1 helicase
functions independently of BRCA1 in the Fanconi anemia pathway for DNA
crosslink repair. Nat Genet 37: 953–957.
37. Ronen A, Glickman BW (2001) Human DNA repair genes. Environ Mol
Mutagen 37: 241–283.
38. Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ, et al. (2000) BASC, a super
complex of BRCA1-associated proteins involved in the recognition and repair of
aberrant DNA structures. Genes Dev 14: 927–939.
39. Riccio A, Aaltonen LA, Godwin AK, Loukola A, Percesepe A, et al. (1999) The
DNA repair gene MBD4 (MED1) is mutated in human carcinomas with
microsatellite instability. Nat Genet 23: 266–268.
40. Wood RD, Mitchell M, Sgouros J, Lindahl T (2001) Human DNA repair genes.
Science 291: 1284–1289.
41. Bensimon A, Schmidt A, Ziv Y, Elkon R, Wang SY, et al. (2010) ATM-
dependent and -independent dynamics of the nuclear phosphoproteome after
DNA damage. Sci Signal 3: rs3.
42. Qin S, Parthun MR (2002) Histone H3 and the histone acetyltransferase Hat1p
contribute to DNA double-strand break repair. Mol Cell Biol 22: 8353–8365.
43. Bracken AP, Ciro M, Cocito A, Helin K (2004) E2F target genes: unraveling the
biology. Trends Biochem Sci 29: 409–417.
44. Nakata K, Tanaka Y, Nakano T, Adachi T, Tanaka H, et al. (2006) Nuclear
receptor-mediated transcriptional regulation in Phase I, II, and III xenobiotic
metabolizing systems. Drug Metab Pharmacokinet 21: 437–457.
45. Meroni G, Diez-Roux G (2005) TRIM/RBCC, a novel class of ‘single protein
RING finger’ E3 ubiquitin ligases. Bioessays 27: 1147–1157.
46. Santamaria I, Velasco G, Pendas AM, Paz A, Lopez-Otin C (1999) Molecular
cloning and structural and functional characterization of human cathepsin F, a
new cysteine proteinase of the papain family with a long propeptide domain.
J Biol Chem 274: 13800–13809.
47. Socha MJ, Manhiani M, Said N, Imig JD, Motamed K (2007) Secreted protein
acidic and rich in cysteine deficiency ameliorates renal inflammation and fibrosis
in angiotensin hypertension. Am J Pathol 171: 1104–1112.
48. Strandjord TP, Madtes DK, Weiss DJ, Sage EH (1999) Collagen accumulation
is decreased in SPARC-null mice with bleomycin-induced pulmonary fibrosis.
Am J Physiol 277: L628–635.
49. Kisseleva T, Brenner DA (2008) Mechanisms of fibrogenesis. Exp Biol Med
(Maywood) 233: 109–122.
50. Atorrasagasti C, Aquino JB, Hofman L, Alaniz L, Malvicini M, et al. (2011)
SPARC down-regulation attenuates the profibrogenic response of hepatic
stellate cells induced by TGF-{beta}1 and PDGF. Am J Physiol Gastrointest
Liver Physiol.
51. Bradshaw AD, Francki A, Motamed K, Howe C, Sage EH (1999) Primary
mesenchymal cells isolated from SPARC-null mice exhibit altered morphology
and rates of proliferation. Mol Biol Cell 10: 1569–1579.
52. Gressner AM, Weiskirchen R, Breitkopf K, Dooley S (2002) Roles of TGF-beta
in hepatic fibrosis. Front Biosci 7: d793–807.
53. Rentz TJ, Poobalarahi F, Bornstein P, Sage EH, Bradshaw AD (2007) SPARC
regulates processing of procollagen I and collagen fibrillogenesis in dermal
fibroblasts. J Biol Chem 282: 22062–22071.
54. Bradshaw AD, Baicu CF, Rentz TJ, Van Laer AO, Bonnema DD, et al. (2010)
Age-dependent alterations in fibrillar collagen content and myocardial diastolic
function: role of SPARC in post-synthetic procollagen processing. Am J Physiol
Heart Circ Physiol 298: H614–622.
55. Benyon RC, Hovell CJ, Da Gaca M, Jones EH, Iredale JP, et al. (1999)
Progelatinase A is produced and activated by rat hepatic stellate cells and
promotes their proliferation. Hepatology 30: 977–986.
56. Radbill BD, Gupta R, Ramirez MC, DiFeo A, Martignetti JA, et al. (2011) Loss
of matrix metalloproteinase-2 amplifies murine toxin-induced liver fibrosis by
upregulating collagen I expression. Dig Dis Sci 56: 406–416.
57. Haimerl F, Erhardt A, Sass G, Tiegs G (2009) Down-regulation of the de-
ubiquitinating enzyme ubiquitin-specific protease 2 contributes to tumor
necrosis factor-alpha-induced hepatocyte survival. J Biol Chem 284: 495–504.
58. Robbiani DF, Finch RA, Jager D, Muller WA, Sartorelli AC, et al. (2000) The
leukotriene C(4) transporter MRP1 regulates CCL19 (MIP-3beta, ELC)-
dependent mobilization of dendritic cells to lymph nodes. Cell 103: 757–768.
59. Reif K, Ekland EH, Ohl L, Nakano H, Lipp M, et al. (2002) Balanced
responsiveness to chemoattractants from adjacent zones determines B-cell
position. Nature 416: 94–99.
60. Bromley SK, Thomas SY, Luster AD (2005) Chemokine receptor CCR7 guides
T cell exit from peripheral tissues and entry into afferent lymphatics. Nat
Immunol 6: 895–901.
61. Rempel SA, Hawley RC, Gutierrez JA, Mouzon E, Bobbitt KR, et al. (2007)
Splenic and immune alterations of the Sparc-null mouse accompany a lack of
immune response. Genes Immun 8: 262–274.
62. Sahin H, Trautwein C, Wasmuth HE (2010) Functional role of chemokines in
liver disease models. Nat Rev Gastroenterol Hepatol 7: 682–690.
63. Atorrasagasti C, Aquino JB, Hofman L, Alaniz L, Malvicini M, et al. (2011)
SPARC downregulation attenuates the profibrogenic response of hepatic stellate
cells induced by TGF-beta1 and PDGF. Am J Physiol Gastrointest Liver Physiol
300: G739–748.
64. Yonezawa T, Kurata R, Kimura M, Inoko H (2011) Which CIDE are you on?
Apoptosis and energy metabolism. Mol Biosyst 7: 91–100.
65. Francki A, McClure TD, Brekken RA, Motamed K, Murri C, et al. (2004)
SPARC regulates TGF-beta1-dependent signaling in primary glomerular
mesangial cells. J Cell Biochem 91: 915–925.
66. Furuyama K, Kawaguchi Y, Akiyama H, Horiguchi M, Kodama S, et al. (2011)
Continuous cell supply from a Sox9-expressing progenitor zone in adult liver,
exocrine pancreas and intestine. Nat Genet 43: 34–41.
Lack of SPARC Ameliorates Hepatic Fibrosis in Mice
PLOS ONE | www.plosone.org 16 February 2013 | Volume 8 | Issue 2 | e54962
67. Hanley KP, Oakley F, Sugden S, Wilson DI, Mann DA, et al. (2008) Ectopic
SOX9 mediates extracellular matrix deposition characteristic of organ fibrosis.
J Biol Chem 283: 14063–14071.
68. Lim YS, Lee HC, Lee HS (2007) Switch of cadherin expression from E- to N-
type during the activation of rat hepatic stellate cells. Histochem Cell Biol 127:
149–160.
69. May P, May E (1999) Twenty years of p53 research: structural and functional
aspects of the p53 protein. Oncogene 18: 7621–7636.
70. Lu S, Shen KC, Wang Y, Brooks SC, Wang YA (2005) Impaired hepatocyte
survival and liver regeneration in Atm-deficient mice. Hum Mol Genet 14:
3019–3025.
71. Dubrovska A, Kanamoto T, Lomnytska M, Heldin CH, Volodko N, et al. (2005)
TGFbeta1/Smad3 counteracts BRCA1-dependent repair of DNA damage.
Oncogene 24: 2289–2297.
72. Satterwhite DJ, Matsunami N, White RL (2000) TGF-beta1 inhibits BRCA1
expression through a pathway that requires pRb. Biochem Biophys Res
Commun 276: 686–692.
73. Rius M, Nies AT, Hummel-Eisenbeiss J, Jedlitschky G, Keppler D (2003)
Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized
to the basolateral hepatocyte membrane. Hepatology 38: 374–384.
74. Aleksunes LM, Scheffer GL, Jakowski AB, Pruimboom-Brees IM, Manautou JE
(2006) Coordinated expression of multidrug resistance-associated proteins (Mrps)
in mouse liver during toxicant-induced injury. Toxicol Sci 89: 370–379.
75. Aleksunes LM, Campion SN, Goedken MJ, Manautou JE (2008) Acquired
resistance to acetaminophen hepatotoxicity is associated with induction of
multidrug resistance-associated protein 4 (Mrp4) in proliferating hepatocytes.
Toxicol Sci 104: 261–273.
Lack of SPARC Ameliorates Hepatic Fibrosis in Mice
PLOS ONE | www.plosone.org 17 February 2013 | Volume 8 | Issue 2 | e54962
